<SEC-DOCUMENT>0000950103-22-013465.txt : 20220802
<SEC-HEADER>0000950103-22-013465.hdr.sgml : 20220802
<ACCEPTANCE-DATETIME>20220802072510
ACCESSION NUMBER:		0000950103-22-013465
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220802
FILED AS OF DATE:		20220802
DATE AS OF CHANGE:		20220802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221126874

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp178142_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of August 2022.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39071</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Biop&ocirc;le</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Route de la Corniche 3B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1066 Epalinges</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 8pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">&#9746;</P>
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 12pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: August 2, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President &amp; General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated August 2, 2022</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp178142_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="image_018.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics to Host Second Quarter 2022
</B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>Financial Results Conference Call on August 9,
2022 </B></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Lausanne, Switzerland, August 2, 2022</B> &ndash;
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30
a.m. ET to report financial results for the second quarter 2022 and provide business updates.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">To access the conference call, please register
<FONT STYLE="color: Blue"><U>here</U></FONT>. Registrants will receive the dial-in number and unique PIN. It is recommended that you
join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under &ldquo;Events
and Presentations&rdquo; in the Investors section of the ADC Therapeutics website at <FONT STYLE="color: Blue"><U>ir.adctherapeutics.com</U></FONT>.
The archived webcast will be available for 30 days following the call.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>About ADC Therapeutics</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).&nbsp;The
Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies
and solid tumors.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics&rsquo; CD19-directed ADC ZYNLONTA<sup>&reg;</sup>
(loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being
evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">ADC Therapeutics is based in Lausanne (Biop&ocirc;le),
Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit <FONT STYLE="color: Blue"><U>https://adctherapeutics.com/
</U></FONT>and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ZYNLONTA<sup>&reg;</sup> is a registered trademark of ADC Therapeutics SA.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>CONTACTS:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Investors</B><BR>
<BR>
</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Eugenia Litz</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">ADC Therapeutics&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>Eugenia.Litz@adctherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Tel.: +44 7879 627205</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">Amanda Hamilton<BR>
ADC Therapeutics<BR>
<FONT STYLE="color: Blue"><U>amanda.hamilton@adctherapeutics.com</U></FONT><BR>
Tel.: +1 917 288 7023</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>Media</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><B></B><BR>
Mary Ann Ondish<BR>
ADC Therapeutics<BR>
<FONT STYLE="color: Blue"><U>maryann.ondish@adctherapeutics.com</U></FONT><BR>
Tel.: +1 914-552-4625</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 )X# 2(  A$! Q$!_\0
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*L)3[.W]/Y;'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
